Manufacturer
ROCHE DIAGNOSTICS GMBH
Contents
Bevacizumab
Indication
In combination w/ fluoropyrimidine-based chemotherapy for metastatic colon or rectum carcinoma. In combination w/ paclitaxel as 1st-line treatment of metastatic breast cancer. In addition to platinum-based chemotherapy as 1st-line treatment of unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer. In combination w/ interferon α-2a as 1st-line treatment of advanced &/or metastatic renal cell cancer. Glioblastoma w/ progressive disease following prior therapy as a single agent. In combination w/ carboplatin & paclitaxel for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. In combination w/ carboplatin & gemcitabine for recurrent, platinum-sensitive, epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior treatment. In combination w/ paclitaxel, topotecan or pegylated liposomal doxorubicin in patients who received no >2 prior chemotherapy regimens & who have not received prior therapy. In combination w/ paclitaxel & cisplatin or paclitaxel & topotecan for persistent, recurrent or metastatic cervix carcinoma.
Instruction
Metastatic colorectal cancer (mCRC) 5 or 10 mg/kg once every 2 wk, or 7.5 or 15 mg/kg once every 3 wk. Metastatic breast cancer (mBC) 10 mg/kg once every 2 wk or 15 mg/kg once every 3 wk. Advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) Addition to cisplatin: 7.5 mg/kg once every 3 wk. Addition to carboplatin: 15 mg/kg once every 3 wk. Advanced &/or metastatic renal cell cancer (mRCC) & glioblastoma 10 mg/kg once every 2 wk. Epithelial ovarian, fallopian tube & primary peritoneal cancer Front-line: 15 mg/kg once every 3 wk in addition to carboplatin & paclitaxel for up to 6 cycles. Recurrent platinum-sensitive: 15 mg/kg once every 3 wk in combination w/ carboplatin & gembitabine for 6 cycles & up to 10 cycles followed by continued use as single agent until disease progression. Recurrent platinum-resistant: 10 mg/kg once every 2 wk in combination w/ paclitaxel, topotecan (given wkly) or pegylated liposomal doxorubicin. Alternatively, 15 mg/kg every 3 wk in combination w/ topotecan given on days 1-5, every 3 wk. Cervical cancer 15 mg/kg once every 3 wk.
Drug interaction
Microangiopathic haemolytic anaemia w/ sunitinib malate.
Malaysia
